Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin, Administered Using Stereotactic Injection to the Striatum of Patients With Bilateral, Idiopathic Parkinson's Disease.

Trial Profile

A Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin, Administered Using Stereotactic Injection to the Striatum of Patients With Bilateral, Idiopathic Parkinson's Disease.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AXO Lenti PD (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Oxford BioMedica
  • Most Recent Events

    • 25 Oct 2018 According to an Axovant Sciences media release, updated data from the study has been presented at the Annual Congress of the European Society of Gene and Cell Therapy and published in Human Gene Therapy, Clinical Development.
    • 09 Oct 2018 According to an Oxford BioMedica media release, data from this study to be Presented at the Annual Congress of the European Society.
    • 17 Mar 2017 According to an Oxford BioMedica media release, follow-up data from the study has been presented in May 2016 at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top